ReviewSeminars in cutaneous medicine and surgery2010
Assessing long-term drug safety: lessons (re) learned from raptiva.
Review in Seminars in cutaneous medicine and surgery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs.PloS one · 2012Trial
- Chitosan alchemy: transforming tissue engineering and wound healing.RSC advances · 2024Review
- The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research.The oncologist · 2023Article
- An activation specific anti-Mac-1 designed ankyrin repeat protein improves survival in a mouse model of acute lung injury.Scientific reports · 2022Article
- Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies.Frontiers in neurology · 2022Article
- Regulatory mechanisms of neutrophil migration from the circulation to the airspace.Cellular and molecular life sciences : CMLS · 2021Review
- CCR7 in Blood Cancers - Review of Its Pathophysiological Roles and the Potential as a Therapeutic Target.Frontiers in oncology · 2021Review
- Anti-αLβ2 antibodies reveal novel endocytotic cross-modulatory functionality.British journal of pharmacology · 2020Article
- A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis.Medicine · 2020Article
- Psoriasis and Treatment: Past, Present and Future Aspects.Acta dermato-venereologica · 2020Review
- Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment.Frontiers in immunology · 2019Review
- Integrins in T Cell Physiology.International journal of molecular sciences · 2018Review
- Old and New Biological Therapies for Psoriasis.International journal of molecular sciences · 2017Review
- Integrins as Therapeutic Targets: Successes and Cancers.Cancers · 2017Review
- Update on psoriasis immunopathogenesis and targeted immunotherapy.Seminars in immunopathology · 2016Review
- A novel multi-parameter assay to dissect the pharmacological effects of different modes of integrin αLβ2 inhibition in whole blood.British journal of pharmacology · 2015Article
- A cutting edge overview: psoriatic disease.Clinical reviews in allergy & immunology · 2013Review
- Learning from disease registries during a pandemic: Moving toward an international federation of patient registries.Clinics in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Efalizumab was approved for moderate to severe psoriasis in 2003 based on studies in approximately 2700 patients, of whom only 218 were exposed to the drug for more than 1 year. In 2009, after more than 46,000 patients were exposed to efalizumab, the drug was withdrawn from the market after 3 confirmed and 1 suspected case of progressive multifocal leukoencephalopathy (PML) were spontaneously reported. As PML is very rare, it is extremely unlikely that the 4 reported cases were due to chance and given that PML occurs primarily in patients who are immunosuppressed, the association is likely causal. The identification of PML as a serious, but statistically rare risk of efalizumab demonstrates the strengths and weaknesses of the current drug approval and pharmacovigilance processes for fully measuring the safety of a drug. Patients and clinicians need to be aware of the relative completeness and limitations of existing safety data of a drug when selecting a treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.